Worse rPFS, OS observed in patients with BRCA-mutated mCRPC vs non-BRCA
“These results further support the importance of screening for germline and somatic BRCA1/2 alterations to deliver more precise care for our patient," says David Olmos, MD, PhD.
FDA fast tracks treatment for immune checkpoint inhibitor–resistant urothelial carcinoma
“There is an urgent need for new treatment options for [patients with] urothelial carcinoma, many of whom find themselves out of options after progressing on immune checkpoint inhibitors," said Sergio Santillana, MD.
Maintenance rucaparib shows promise in urothelial carcinoma with DNA repair deficiency
In a phase 2 trial, patients with metastatic urothelial carcinoma and DNA repair deficiency who had not progressed on chemotherapy were randomized to either rucaparib maintenance or placebo.
ARASENS darolutamide safety update shows no increased toxicity in men with mHSPC
Adding darolutamide to androgen deprivation therapy and docetaxel did not increase the incidence or severity of adverse events in patients with metastatic hormone-sensitive prostate cancer.
Atezolizumab falls short in advanced penile cancer trial
Immunotherapy with or without radiotherapy did not demonstrate significant efficacy in patients with advanced squamous cell carcinoma of the penis, according to findings from the phase 2 PERICLES trial.
2 Commerce Drive Cranbury, NJ 08512